Cargando…

Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants

Detalles Bibliográficos
Autores principales:	Pallett, Scott J C, Heskin, Joseph, Groppelli, Elisabetta, Mazzella, Andrea, Moore, Luke S P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Author(s). Published by Elsevier Ltd. 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8700647/ https://www.ncbi.nlm.nih.gov/pubmed/34977829 http://dx.doi.org/10.1016/S2666-5247(21)00337-2

Ejemplares similares

Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis
por: Cromer, Deborah, et al.
Publicado: (2022)

Risk of omicron infection for high-risk older adults in long-term care facilities
por: Pallett, Scott J C, et al.
Publicado: (2023)

Neutralising activity and antibody titre in 10 patients with breakthrough infections of the SARS-CoV-2 Omicron variant in Japan
por: Okumura, Nobumasa, et al.
Publicado: (2022)

Early identification of high-risk individuals for monoclonal antibody therapy and prophylaxis is feasible by SARS-CoV-2 anti-spike antibody specific lateral flow assay
por: Pallett, Scott J.C., et al.
Publicado: (2022)

SARS-CoV-2 neutralising antibody testing in Europe: towards harmonisation of neutralising antibody titres for better use of convalescent plasma and comparability of trial data
por: Nguyen, Dung, et al.
Publicado: (2021)

Neutralisation of ZF2001-elicited antisera to SARS-CoV-2 variants
por: Zhao, Xin, et al.
Publicado: (2021)

Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies
por: Yamasoba, Daichi, et al.
Publicado: (2022)

SARS-CoV-2 neutralising antibodies after bivalent versus monovalent booster
por: Wang, Qian, et al.
Publicado: (2023)

Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac
por: Chen, Yuxin, et al.
Publicado: (2021)

AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC
por: Wall, Emma C, et al.
Publicado: (2021)

SARS-CoV-2 spike E484K mutation reduces antibody neutralisation
por: Jangra, Sonia, et al.
Publicado: (2021)

Resistance of SARS-CoV-2 omicron subvariant BA.4.6 to antibody neutralisation
por: Wang, Qian, et al.
Publicado: (2022)

Caution required with use of ritonavir-boosted PF-07321332 in COVID-19 management
por: Heskin, Joseph, et al.
Publicado: (2022)

Optimising the initial investigation of suspected cases of SARS-CoV-2 reinfection
por: Pallett, Scott JC., et al.
Publicado: (2021)

Structured serological testing is an essential component to investigating SARS-CoV-2 reinfection
por: Pallett, Scott J C, et al.
Publicado: (2021)

Neutralisation sensitivity of the SARS-CoV-2 XBB.1 lineage
por: Arora, Prerna, et al.
Publicado: (2023)

Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum
por: Dejnirattisai, Wanwisa, et al.
Publicado: (2022)

SARS-CoV-2 antibody prevalence, titres and neutralising activity in an antenatal cohort, United Kingdom, 14 April to 15 June 2020
por: Lumley, Sheila F, et al.
Publicado: (2020)

Serum neutralisation of the SARS-CoV-2 omicron sublineage BA.2
por: Chen, Lin-Lei, et al.
Publicado: (2022)

The effect of cilgavimab and neutralisation by vaccine-induced antibodies in emerging SARS-CoV-2 BA.4 and BA.5 sublineages
por: Arora, Prerna, et al.
Publicado: (2022)

Neutralisation sensitivity of the SARS-CoV-2 omicron BA.2.75 sublineage
por: Gruell, Henning, et al.
Publicado: (2022)

Three-dose vaccination elicits neutralising antibodies against omicron
por: Wu, Mary, et al.
Publicado: (2022)

SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination
por: Behrens, Georg MN, et al.
Publicado: (2021)

Neutralising antibodies after COVID-19 vaccination in UK haemodialysis patients
por: Carr, Edward J, et al.
Publicado: (2021)

Neutralizing antibody titres in SARS-CoV-2 infections
por: Lau, Eric H. Y., et al.
Publicado: (2021)

Evasion of neutralising antibodies by omicron sublineage BA.2.75
por: Sheward, Daniel J, et al.
Publicado: (2022)

A protein subunit vaccine booster following two doses of inactivated SARS-CoV-2 vaccine provides high neutralisation of SARS-CoV-2 and its variants in mice
por: Zhang, Rong, et al.
Publicado: (2022)

Neutralisation titres against SARS-CoV-2 are sustained 6 months after onset of symptoms in individuals with mild COVID-19
por: Underwood, Alexander P., et al.
Publicado: (2021)

Host cell entry and neutralisation sensitivity of the SARS-CoV-2 XBB.1.16 lineage
por: Nehlmeier, Inga, et al.
Publicado: (2023)

Neutralisation of HIV-1 cell-cell spread by human and llama antibodies
por: McCoy, Laura E, et al.
Publicado: (2014)

Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination
por: Wall, Emma C, et al.
Publicado: (2021)

Omicron neutralising antibodies after COVID-19 vaccination in haemodialysis patients
por: Carr, Edward J, et al.
Publicado: (2022)

Ongoing sporadic monkeypox cases: neutralising antibody detection in asymptomatic individuals
por: Moschese, Davide, et al.
Publicado: (2023)

Comparative neutralisation profile of SARS-CoV-2 omicron subvariants BA.2.75 and BA.5
por: Tan, Chee-Wah, et al.
Publicado: (2022)

Serological assays for delayed SARS-CoV-2 case identification – Author's reply
por: Pallett, Scott J C, et al.
Publicado: (2020)

Glycan masking of a non-neutralising epitope enhances neutralising antibodies targeting the RBD of SARS-CoV-2 and its variants
por: Carnell, George W., et al.
Publicado: (2023)

Post-recovery enhancement of anti-variant neutralisation after severe COVID-19
por: Lu, Yingying, et al.
Publicado: (2022)

Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3
por: Arora, Prerna, et al.
Publicado: (2022)

Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer
por: Fendler, Annika, et al.
Publicado: (2022)

Hybrid immunity in older adults is associated with reduced SARS-CoV-2 infections following BNT162b2 COVID-19 immunisation
por: Pallett, Scott J. C., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_efrojeb007uhiporqfl6foej84